GlaxoSmithKline Given Buy Rating at Bank of America Corp. (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reiterated by investment analysts at Bank of America Corp. in a note issued to investors on Monday, Analyst Ratings Network reports. They currently have a GBX 2,050 ($32.84) price target on the stock. Bank of America Corp.’s target price would suggest a potential upside of 28.97% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Friday. They now have a GBX 1,900 ($30.43) price target on the stock. Separately, analysts at Shore Capital Stockbrokers reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Friday. Finally, analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline (LON:GSK) from GBX 1,960 ($31.40) to GBX 1,850 ($29.63) in a research note to investors on Tuesday, September 17th. They now have a “buy” rating on the stock.
Five equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of GBX 1,639.43 ($26.26).
Shares of GlaxoSmithKline (LON:GSK) traded up 0.79% on Monday, hitting GBX 1589.50. The stock had a trading volume of 7,235,815 shares. GlaxoSmithKline has a one year low of GBX 1194.5601 and a one year high of GBX 2076.00. The stock’s 50-day moving average is GBX 1652. and its 200-day moving average is GBX 1640.. The company’s market cap is £77.011 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.